Investing Profile

Daniel Lynch

InvestorVC
Executive Chairman at GRA Venture Fund
gv.com/team/dan-lynch/Boston, Massachusetts
Photo of Daniel Lynch, GRA Venture Fund, LLC
Your Intro Paths to Daniel Lynch

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Networks Daniel is a member of
Les Fermes ExotiQC Network
435 CONNECTIONS
Les Fermes ExotiQC Network
435 CONNECTIONS
Les Fermes ExotiQC Network
435 CONNECTIONS
Les Fermes ExotiQC Network
435 CONNECTIONS
GRA Venture Fund Network
405 CONNECTIONS

Find Daniel Lynch on

cb
Current Investing Position
GRA Venture Fund, LLC
Investment Range
$250K - $50.0M
Sweet Spot
$25.0M
Investments On Record
4
Current Fund Size
$25.1M

Daniel Lynch is on these Sector & Stage Rankings

Daniel Lynch's Investments On Record (3)

CompanyStageDateRound SizeTotal Raised
Tome Biosciences
Series ADec 2023$210M
$210M
Co-investors: Jorge Conde (Andreessen Horowitz), Alan Crane (Polaris Partners), Jay Markowitz (ARCH Venture Partners)
Blueprint Medicines
Series BJan 2014$25M
$65M
Co-investors: Stephen Knight (F-Prime Capital (formerly Fidelity Biosciences)), Thilo Schroeder (Nextech Invest)
Sesen Bio
Series AMay 2012$20M
Series AMar 2010$35M
$55M
Co-investors: Noubar Afeyan (Flagship Pioneering), David Berry (Flagship Ventures), Cary Pfeffer (Third Rock Ventures)

Daniel Lynch's Experience

Executive Chairman Les Fermes ExotiQCPresent
Executive Chairman GRA Venture FundPresent
Chairman of the Board Les Fermes ExotiQCPresent
Chairman of the Board GRA Venture FundPresent
Board Member Les Fermes ExotiQCPresent
Board Member GRA Venture FundPresent
Chairman Of The Board Les Fermes ExotiQCPresent
Chairman Of The Board GRA Venture FundPresent
Finance Bristol Myers SquibbPresent
Chairman of the Board Bluebird BioPresent
Board Member Ember TherapeuticsPresent
Chairman of the Board BIND TherapeuticsPresent
Chairman Of The Board Stromedix Inc.Present
Executive Chairman Nimbus TherapeuticsPresent
Chairman Of The Board Blueprint MedicinesPresent
Chairman Of The Board Surface Oncology Inc.Present
Chairman of the Board SpringWorks TherapeuticsPresent
Chairman Of The Board Xilio Therapeutics, Inc.Present
CEO ImClone Systems, a wholly-owned subsidiary of Eli Lilly and CompanyPresent

Daniel Lynch's Education

Wesleyan University Bachelor of Arts (B.A.) Mathematics

Investors who invest with Daniel Lynch

Sign in with Google →

Scouts & Angels Affiliated With Daniel Lynch

Sign in with Google →